Patel Sanj K 4

What Happened
Sanj K. Patel, Chairman and CEO of Kiniksa Pharmaceuticals (KNSA), exercised options and converted/received shares on April 6–7, 2026 and monetized a portion of them. On April 6 he exercised options to acquire 7,278 shares at an exercise price of $10.36 (cost ≈ $75,400) and sold those 7,278 shares in the open market at a weighted-average price of $50.01 for proceeds of about $363,973. On April 7 he had an additional 9,991-share exercise/conversion reported; 4,831 shares were surrendered/withheld to cover taxes/withholding at $48.94 (value ≈ $236,429). The filings also show derivative conversions reported at $0, reflecting settlement/conversion of equity awards (e.g., RSUs).

Key Details

• Transaction dates: April 6–7, 2026. Form 4 filed April 8, 2026 (not late).
• April 6: Exercise of 7,278 shares @ $10.36 (cost ≈ $75,400) and sale of 7,278 shares @ weighted $50.01 (proceeds ≈ $363,973). Sale executed in multiple trades at $50.005–$50.03; $50.01 is the weighted average (footnote F2).
• April 7: Exercise/conversion of 9,991 shares (acquisition reported; exercise price shown as N/A) and withholding/surrender of 4,831 shares @ $48.94 to cover taxes (value ≈ $236,429).
• Sale disposition was effected pursuant to a 10b5‑1 plan executed October 31, 2025 (footnote F1).
• Footnotes: RSUs convert to one Class A share each (F3); option was fully vested/exercisable (F4); RSUs vest over four years with 25% annually from April 7, 2022 (F5).
• Shares owned after the transactions: not specified in the provided filing summary.

Context

• This was an exercise followed by sales (a common liquidity event). Some shares were sold in the open market while others were surrendered/withheld to satisfy tax obligations — effectively a cashless/withholding settlement for part of the exercise.
• 10b5‑1 plan sales are pre-scheduled transactions and are generally viewed as routine rather than a real-time statement of sentiment.
• For retail investors: purchases by insiders can be stronger signals than routine exercises/sales; here the primary activity was monetization after exercising vested awards.